Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis
Crossref DOI link: https://doi.org/10.1007/s12325-019-00986-7
Published Online: 2019-05-30
Published Print: 2019-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Patel, Dipen
Shelbaya, Ahmed
Cheung, Raymond
Aggarwal, Jyoti
Park, Sang Hee
Coindreau, Javier
Funding for this research was provided by:
Pfizer Inc
Text and Data Mining valid from 2019-05-30
Version of Record valid from 2019-05-30
Article History
Received: 9 April 2019
First Online: 30 May 2019